Loading…
Loading…
CUTR (Cutera, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
CUTR does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CUTR and 80,000+ other tickers.
See exactly how CUTR's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CUTR and 80,000+ other tickers.
Cutera, Inc. is a medical technology enterprise specializing in the research, development, manufacturing, marketing, and servicing of cutting-edge laser and energy-based aesthetic systems for medical professionals worldwide. The company's comprehensive product line includes several advanced devices: Secret PRO, an innovative system combining fractional CO2 technology for thorough skin resurfacing with radio frequency (RF) microneedling for deep dermal tissue restructuring. truSculpt flex, a bio-electrical muscle stimulation apparatus engineered to support individuals across all fitness…
BRISBANE, Calif.--(BUSINESS WIRE)-- #aesthetics--CUTERA, INC., a leading provider of aesthetic and dermatologic solutions, today announced a strategic partnership with Restimulate Health, an innovative healthcare provider focused on optimizing rehabilitation outcomes. Through this collaboration, Restimulate Health will incorporate Cutera's truFlex technology into its clinically developed proprietary neuromuscular activation protocols to support muscle activation, strength development, and muscle re-education.
BRISBANE, Calif.--(BUSINESS WIRE)-- #aesthetics--CUTERA, INC., a leading provider of aesthetic and dermatological solutions, announces today the appointments of Chris House as Chief Technology Officer and Charles Hunt as Vice President of Design and Experience. These strategic appointments underscore Cutera's commitment to next-generation solutions and customer-centered product development. As Chief Technology Officer, Chris House will lead Cutera's global technology and product development strategy, focusin.
BRISBANE, Calif.--(BUSINESS WIRE)--CUTERA, INC., (“Cutera” or “the Company”), a leading provider of aesthetic and dermatology solutions, today announced that the Company has successfully completed its financial restructuring process and emerged from Chapter 11. Cutera emerges with a significantly stronger balance sheet, well positioned to drive innovation and growth. Through this process, Cutera has reduced its debt by nearly $400 million, or over 90%, and raised $65 million in new money financ.
BRISBANE, Calif.--(BUSINESS WIRE)--Cutera, Inc. (“Cutera” or the “Company”) (Nasdaq: CUTR) today announced that it has formally notified The Nasdaq Stock Market LLC (“Nasdaq”) of its intent to voluntarily delist its common stock from the Nasdaq Global Select Market. Cutera expects to file a Form 25 with the Securities and Exchange Commission (the "SEC") relating to the voluntary delisting of its common stock on or about March 20, 2025. The Company expects the delisting of the common stock to be.
BRISBANE, Calif.--(BUSINESS WIRE)--CUTERA, INC., (“Cutera” or “the Company”), a leading provider of aesthetic and dermatology solutions, today announced that it is initiating a restructuring transaction with the support of a group of existing lenders, representing approximately 74% of the Company's notes, to strengthen its balance sheet and position Cutera for long-term success. Through the transaction, Cutera will reduce its debt by nearly $400 million, or over 90%, and raise $65 million in ne.